ExocoBio Inc., a global bio venture company in Exosome field attains home and abroad attention with its excellent technology and feasibility. Recently, ExocoBio Inc. was introduced to 'Top 4 most richly Funded Exosome Startups' uncased by 'Bioinformant' which is a global market research company specialized in stem cell.
'Exosome' is a nanometer size vesicle that different materials such as nucleic acid, protein, lipids, and low molecular substance in a cell. exosome drew attention in the pharmaceutical/bio market as the fact that various materials are nested in exsome depending on types of cell being revealed.
Besides, ExocoBio, Codiak Biosciences (USA), a developer of anticancer medicine based on
exosome, Exosome Diagnostics (USA), a diagnosis company using nucleic acid material in exosome, and Evox Therapeutics(UK), a developer of cardiac medicine originated from exosome are included in the list of 'Top 4 most richly- Funded Exosome Startups' by Bioinformant.
ExocoBio succeeded in series A investment totaling 12.5 billion Won only in about 100 days from its foundation in last April. Following this, they presented a thesis to confirm the stem cell exosome's feasibility in atopic dermatitis improvement and successfully completed Series B investment of 30 billion Won last September. This ranks 1st track record in Korea and 3rd in World investment performance.
ExocoBio Inc., a global bio venture company in Exosome field attains home and abroad attention with its excellent technology and feasibility. Recently, ExocoBio Inc. was introduced to 'Top 4 most richly Funded Exosome Startups' uncased by 'Bioinformant' which is a global market research company specialized in stem cell.
'Exosome' is a nanometer size vesicle that different materials such as nucleic acid, protein, lipids, and low molecular substance in a cell. exosome drew attention in the pharmaceutical/bio market as the fact that various materials are nested in exsome depending on types of cell being revealed.
Besides, ExocoBio, Codiak Biosciences (USA), a developer of anticancer medicine based on
exosome, Exosome Diagnostics (USA), a diagnosis company using nucleic acid material in exosome, and Evox Therapeutics(UK), a developer of cardiac medicine originated from exosome are included in the list of 'Top 4 most richly- Funded Exosome Startups' by Bioinformant.
ExocoBio succeeded in series A investment totaling 12.5 billion Won only in about 100 days from its foundation in last April. Following this, they presented a thesis to confirm the stem cell exosome's feasibility in atopic dermatitis improvement and successfully completed Series B investment of 30 billion Won last September. This ranks 1st track record in Korea and 3rd in World investment performance.